MARKET OVERVIEW The global hyperlipidemia drugs market is poised for steady growth, driven by the rising prevalence of cardiovascular diseases linked to sedentary lifestyles, obesity, and poor dietary habits. Valued at USD 23.08 billion in 2024, the market is projected to reach USD 27.18 billion by 2033, exhibiting a CAGR of 1.69% during the forecast period. Key factors fueling this growth...